Aclaris Therapeutics vs Upstream Bio
ACRS and UPB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and UPB compare
Aclaris Therapeutics is the larger company, worth 3.8 times as much as Upstream Bio ($577M against $152M).
Upstream Bio grew revenue faster over the last twelve months (2.5% versus −59.3% for Aclaris Therapeutics).
Aclaris Therapeutics keeps more of each dollar of sales as profit, with a net margin of −1244% compared with −5712% at Upstream Bio.
Upstream Bio scores higher on the StockData Score (8 against 6 for Aclaris Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | UPB |
|---|---|---|
| Size and price | ||
| Market cap | $577M | $152M |
| Share price | $3.92 | $2.78 |
| Change, 1 year | 62.7% | −88.3% |
| Change, 5 years | −71.6% | – |
| Beta (5Y) | 1.13 | 1.28 |
| Employees | 73 | 75 |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 90.1× | 53.1× (better) |
| P/B | 3.5× | 0.7× (better) |
| FCF yield | −13.1% | – |
| Growth | ||
| Revenue growth (TTM) | −59.3% | 2.5% (better) |
| Revenue growth, 5Y average | 3.8% | – |
| Profitability | ||
| Gross margin | 79.2% | – |
| Operating margin | −1414% (better) | −6116% |
| Net margin | −1244% (better) | −5712% |
| FCF margin | −1177% | – |
| Return on equity | −55.5% | −53.5% (better) |
| Return on invested capital | – | −846% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.09 | 20.45 (better) |
| Altman Z-score | −0.44 | 3.80 (better) |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 92.3% |
| Held by insiders | 13.3% | 8.6% |
| Insider net buying, 12 months | −$1.4M | −$105K (better) |
| Short interest, % of float | 9.1% | 7.1% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- UPB stock overview
- UPB income statement
- UPB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.